Pursennide

Quick links to important sections

Pursennide

Selected form

Method of action: Laxative

Treatment option: Constipation, Colonoscopy, Proctitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pursennide

This section provides the foundational identity, composition, and general classification of the medicine Pursennide, maintaining maximum semantic density and factual accuracy.

Property Description
Active Ingredient Sennosides A and B (Calcium salts)
Form Coated tablet (Oral formulation)
Pharmacological Class Stimulant Laxative (ATC A06AB06)
Common Use Short-term relief of occasional constipation
Origin Naturally derived from the Senna plant

What Type of Medicine is Pursennide?

Pursennide is a medicinal product classified as a stimulant laxative primarily used for the short-term treatment of occasional constipation. The drug's core identity is based on its active ingredients, the sennosides (Sennoside A and Sennoside B). These compounds are internationally recognized for their action in the large intestine. The classification as a stimulant laxative defines it as a substance that directly acts on the intestinal lining to promote movement, which has been clinically recognized for decades of use in this therapeutic area. The product is frequently positioned as an accessible, over-the-counter (OTC) option for adults seeking relief from temporary periods of constipation.


Composition, Origin, and Available Form

The active substances, sennosides, are naturally derived compounds classified chemically as anthraquinone glycosides. They are extracted from the leaves and pods of the Senna plant (Cassia angustifolia or C. senna), confirming its botanical origin. Pursennide is typically supplied as an oral formulation, most commonly in the form of a coated tablet. This presentation is designed as a single-ingredient product, ensuring the active component is delivered reliably to the lower gastrointestinal tract, its required site of action.


How Pursennide Generally Functions

Pursennide's general function is to stimulate propulsive movements and increase moisture within the colon, enabling easier passage of matter. The substance is inert upon ingestion and requires activation by colonic bacteria before it can begin its work, which results in its characteristic delayed onset of action, typically taking six to twelve hours after administration. The activated compound works by both intensifying the intestinal muscle contractions that move contents forward while also influencing fluid balance to help soften the stool. This combined effect ensures a predictable and reliable therapeutic outcome.

Regulatory References

  1. EMA Herbal Monograph on Senna leaf
  2. Senna - Drugs and Lactation Database (LactMed)

What side effects are possible with Pursennide?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety restrictions for Pursennide (Senna glycosides), as established in regulatory labeling (e.g., Summary of Product Characteristics, SmPC).

Adverse Reactions

The most frequent and expected adverse events are generally related to the gastrointestinal system. These include abdominal pain, cramps, and diarrhea.

Category Documented Adverse Reactions
Common / Expected Abdominal discomfort, Diarrhea, Nausea
Other Effects Yellow-brownish or reddish discoloration of urine (chromaturia)

Serious Safety Risks and Contraindications

The most clinically significant risk is the potential for severe loss of fluid and electrolytes, primarily hypokalaemia (low potassium), especially with overuse or prolonged treatment. Hypokalaemia can lead to serious complications such as muscle weakness and cardiac issues. Megacolon and dependence (habituation) have been reported with long-term use.

Pursennide is strictly contraindicated (must not be used) in patients with:

  • Gastrointestinal obstruction or narrowing (e.g., ileus).
  • Acute inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis).
  • Severe dehydration involving electrolyte loss.
  • Undiagnosed acute abdominal pain.

Regulatory Safety Limitations

Official labeling mandates that use must be strictly short-term (e.g., no longer than seven days) to mitigate the risks of dependence and functional deterioration of the bowel. It is generally not recommended for use in children under a specified age without medical direction. Patients with existing cardiac or kidney conditions may be at increased risk of electrolyte imbalance and require particular caution.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

The official regulatory documentation describes the signs of an acute overdose of Pursennide (Sennosides) as primarily relating to its excessive pharmacological action. The documented clinical manifestations include severe diarrhoea, intense abdominal pain, and spasms. These effects result in consequential fluid loss and electrolyte imbalance.

Overdosage, particularly in chronic or severe acute situations, carries the documented risk of hypokalaemia (potassium depletion), which can lead to more serious outcomes such as cardiac disorders and muscular weakness. For the elderly, regulators emphasize the critical need to monitor fluid and electrolyte status due to increased susceptibility to these disturbances.

Emergency Regulatory Guidance

Action Requirement (Label-Derived)
Immediate Help Immediately contact a doctor or Poison Control Center in case of accidental overdose [FDA DailyMed].
Antidote Status No specific antidote is known for sennosides overdose [Regulatory consensus].
Management Treatment is symptomatic and supportive, focused on the mandated replacement of fluid and electrolytes lost due to severe diarrhoea [EMA SmPC].

Urgent medical attention is required whenever accidental overdose or signs of severe dehydration and electrolyte depletion are suspected.

Therapeutic Uses of Pursennide

What Pursennide Treats: Main Uses and Benefits

Pursennide is commonly used to help with symptoms related to physical discomfort associated with occasional constipation. It is applied across domains where additional symptomatic support is needed for these episodic or fluctuating manifestations. The medication supports the patient during difficult episodes by easing distress and contributing to improved comfort.


Targeting Occasional and Episodic Constipation

Pursennide is a supportive therapeutic option used in situations involving certain distressing symptoms that arise from an acute or temporary period of infrequent bowel movements. The medicine provides support that helps ease the overall symptom burden, contributing to a more stable intestinal rhythm and improved comfort. The primary symptomatic focuses include general occasional constipation and issues of hard stool consistency.

“Its role is to provide support during temporary episodes of constipation, assisting with maintaining functional stability.”

Supportive Use and Symptom Management

The medicine is applied in scenarios where additional management of discomfort is required, such as managing constipation that arises due to travel, changes in routine, or during the postoperative period. It is relevant when supportive symptom management is appropriate for symptoms that interfere with daily comfort. This supportive role is considered relevant in conditions where symptoms may intensify temporarily, where the medication assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Difficult Evacuation

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Pursennide — Official Regulatory Information

The eligibility profile for Pursennide (Sennosides) is formally defined by official regulatory bodies, primarily through patient contraindications and restrictions related to age and pre-existing medical conditions.


Populations for whom use is Contraindicated (Must Not Use):

  • Patients with hypersensitivity or allergy to sennosides or any of the product’s excipients.
  • Individuals with pre-existing or acute gastrointestinal conditions, including inflammatory bowel diseases (such as ulcerative colitis or Crohn's disease).
  • Those experiencing unexplained abdominal pain (stomach pain), nausea, or vomiting.
  • Conditions such as intestinal obstruction (bowel blockage) or stenosis (narrowing of the gut).

Age-Related Eligibility Rules:

  • Use is generally contraindicated in children under 12 years of age unless explicitly directed by a healthcare professional.
  • The medicine is intended for use in adults and adolescents aged 12 years and older, provided no other contraindications are present.

Conditional or Restricted Use:

  • Pregnancy: Use requires medical consultation before being taken.
  • Lactation (Breastfeeding): Use is generally discouraged or requires professional advice, despite some data suggesting a low level of transfer into breast milk.
  • The medication is explicitly for short-term, occasional use. Prolonged or chronic use is not recommended and may lead to dependence.

What should I know about interactions with other medicines?

The official regulatory profile for Pursennide is defined by interactions resulting from the potential for electrolyte imbalance, specifically potassium depletion (hypokalaemia), associated with its prolonged or excessive use. No interactions related to major metabolic enzymes or drug transporters are formally documented in official labeling.

The primary interaction pattern is classified as pharmacodynamic, where hypokalaemia mediates the functional outcome of co-administered medicines that are sensitive to, or further contribute to, low potassium levels. The regulatory information identifies the following categories of products that require caution:

  • Cardiac Glycosides (e.g., Digoxin): Hypokalaemia can potentiate the therapeutic or toxic actions of these agents.
  • Diuretics and Adrenocorticosteroids: Concomitant use may enhance the risk of severe potassium depletion.
  • Antiarrhythmic Medicinal Products (e.g., Quinidine) and medicines inducing QT-prolongation: These agents interact with hypokalaemia, increasing the risk of cardiac disorders.
  • Liquorice Root: Co-administration with this herbal product may also enhance electrolyte imbalance.

The interaction-related restriction is that co-administration with these substances necessitates monitoring. The regulatory profile is strictly limited to these risk-based interactions contingent on potential hypokalaemia, without any mandatory dose separation requirements or formally designated contraindicated combinations.

Mechanism of Action

Pursennide contains sennosides, which are metabolized by colonic bacteria into the active form, rhein-9-anthrone. This active metabolite exhibits a dual mechanism of action at the level of the colon.

Modulation of Epithelial Transport

Rhein-9-anthrone interacts with the colonic mucosa, causing an inhibition of sodium/potassium ATPase at the serosal membrane. This action decreases net absorption of water and electrolytes from the colonic lumen. Concurrently, it stimulates chloride secretion from the epithelial cells into the lumen, which increases net fluid movement into the colonic lumen. The elevated water content of the fecal mass reduces its structural rigidity.

Stimulation of Motility

The metabolite also directly stimulates colonic myenteric plexi, leading to increased colonic motility and peristalsis. This stimulation initiates the defecation reflex and facilitates increased frequency of colonic evacuation. The combined osmotic and secretagogue actions generate increased intraluminal pressure and mass movement.

Dosage and Administration Information

The administration of Pursennide (sennosides) is based on specific usage principles which define its role as an oral, short-term medication. The recognized route of administration is oral, typically using a coated tablet that must be swallowed whole with fluid and not chewed or crushed.

Official Usage Patterns

The medicine is intended for short-term treatment only, with continuous administration limited to a maximum course of seven to ten days. The general usage principle dictates that the medicine should be initiated at the lowest dose necessary to achieve the desired effect.

For adults and children aged 12 years and over, the standard starting dose is equivalent to 15 mg to 30 mg of sennosides per day. The standard instruction is that the maximum daily dose indicated for the product must never be exceeded.

Administration Schedule

Instruction Detail
Route of administration Oral
Dosing schedule Equivalent to 15 mg to 30 mg of sennosides, taken once daily.
Timing Administered in a single dose, preferably in the evening at bedtime.
Age-group rules Use is not recommended for children under 12 years unless explicitly advised by a physician.

The administration schedule is structured for a single dose in the evening to coordinate the medicine's characteristic 6-to-12-hour action delay with the user's morning routine. If a dose is missed, the standard protocol is to skip the missed dose and resume the regular schedule, avoiding any double dose.

Recent Clinical Evidence

Recent Clinical Evidence

Pursennide contains sennosides, which are stimulant laxatives derived from the Senna plant. Research on this class of compounds focuses primarily on the symptomatic relief of occasional constipation. Clinical studies examine how these agents affect colon motility and hydration, typically evaluating outcomes over short periods due to their classification.

Efficacy and Study Outcomes

Studies examining sennosides generally confirm their laxative action. A systematic review assessing over-the-counter treatments found good evidence supporting the use of sennosides for chronic constipation management in adults.

  • Onset of Action: The typical time to the first bowel movement following oral administration of sennoside products is generally documented within 6 to 12 hours.
  • Comparative Data: Some randomized controlled trials (RCTs) have compared senna with other laxatives, such as lactulose, in specific patient groups (e.g., those with opioid-induced constipation), finding sennosides to be comparable in efficacy and safety profiles in these limited contexts.

Safety and Tolerability Profiles

Clinical data consistently report that sennosides are generally well-tolerated in the adult population when used for short-term treatment. The most commonly reported side effects in studies are gastrointestinal, including abdominal discomfort, cramps, and diarrhea. Prolonged use is not generally recommended in clinical guidelines and has been associated with:

Observation in Studies Context
Electrolyte imbalances Hypokalemia (low potassium) noted in cases of excessive use.
Deterioration of intestinal function Reported after chronic, long-term administration.

It is important to note that the information presented here is descriptive of what was documented in clinical research and does not constitute a recommendation or medical advice. Treatment options should always be discussed with a healthcare provider.

Frequently Asked Questions (FAQ)

Common questions about Pursennide (FAQ)


Q: What happens if I forget to take a dose of Pursennide?

A: According to the official product information, if a dose is missed, regulatory guidance generally advises skipping the missed dose. The instructions mandate resuming the regular schedule and avoiding taking a double dose to compensate for the one that was forgotten.


Q: Can Pursennide be taken with painkillers like paracetamol or ibuprofen?

A: Official drug interaction information generally shows no major interaction between the active ingredient in Pursennide (sennosides) and common over-the-counter painkillers like paracetamol or ibuprofen. However, regulatory bodies note that consultation with a healthcare professional regarding all co-administered medicines is important.


Q: How long does the effect of a single dose of Pursennide usually last?

A: Pursennide is a delayed-action medicine because it needs time to reach the colon and be activated by bacteria. Studies and official product information indicate that the time to the first bowel movement typically occurs after a delay of 8 to 12 hours after administration.


Q: Is Pursennide likely to interact with blood pressure medication?

A: Regulatory warnings specifically note that Pursennide may interact with certain blood pressure medicines called diuretics. Concomitant use with diuretics may enhance the risk of severe hypokalaemia, which is a potentially serious lowering of potassium levels in the blood and a required caution in regulatory labeling.


Q: Are there any herbal supplements that are known to interact with Pursennide?

A: Yes, official regulatory documents indicate that co-administration with the herbal product Liquorice Root may enhance the risk of electrolyte imbalance. This is because both substances can affect potassium levels in the body.


Q: Can Pursennide be taken while using contraceptive pills?

A: Official warnings state that if the medicine causes severe diarrhea or vomiting, the effectiveness of oral contraceptive pills may potentially be reduced. This circumstance may require seeking professional guidance regarding contraceptive methods.


Q: What should I know about pregnancy and Pursennide use?

A: Regulatory information states that use during pregnancy requires medical consultation before being taken. Similarly, due to the small amounts of active metabolites that may pass into breast milk, use while breastfeeding is generally discouraged or requires professional advice.


Q: Are there different strengths of Pursennide available?

A: The active ingredient sennosides is sold under various brands and formulations across different markets. This active compound is commonly available in several tablet strengths, such as 7.5 mg, 8.6 mg, 15 mg, and 25 mg, depending on the specific product brand and region.


Q: Does taking Pursennide with or without food make a difference?

A: Regulatory instructions state that the tablet should be swallowed whole with fluid, such as a glass of water, and is preferably taken in the evening at bedtime. There is no explicit warning in official documentation that states food must be specifically included or avoided.


Q: Does Pursennide cause any long-term effects if used repeatedly?

A: Official warnings emphasize that this medicine is strictly for short-term use only and is not recommended for repeated long-term administration. Prolonged use is associated with risks such as dependence on laxatives, impaired function of the intestine, and disorders in water and electrolyte balance.


Q: Does Pursennide have any reported food interactions?

A: While it is not a direct interaction, regulatory warnings note that chronic use of sennosides may potentially reduce the absorption of certain fat-soluble vitamins (A, D, E, K) and minerals. This is another factor reinforcing why short-term, occasional use is officially advised.


Q: What does it mean if Pursennide doesn't seem to be working for me?

A: If the medicine does not produce the expected effect within the usual timeframe, official guidance notes that consultation with a healthcare provider is recommended. Regulatory information also advises seeking medical guidance if the constipation or abdominal pain persists or worsens after using the medicine.


Q: Is it normal to feel bloated when first taking Pursennide?

A: Yes, official safety information reports that common gastrointestinal side effects may occur. These can include abdominal discomfort, cramps, and diarrhea, and in some regulatory texts, bloating and flatulence are explicitly listed as reported adverse events.


Q: Can a person with diabetes use Pursennide?

A: This question cannot be directly answered using the strict regulatory documentation for sennosides, as diabetes is not listed as an explicit contraindication or special precaution in the official warnings. For any pre-existing health condition, consulting a healthcare professional is important.


Q: Does Pursennide affect the absorption of vitamins or nutrients?

A: Official warnings state that the medicine is strictly for short-term use because chronic administration may reduce the body's ability to absorb certain fat-soluble vitamins and minerals. This reinforces the regulatory requirement to avoid prolonged use.


Q: Can Pursennide be used by people with a history of Irritable Bowel Syndrome (IBS)?

A: While the medicine is strictly contraindicated in inflammatory bowel diseases (like Crohn's), some regulatory documents report that side effects such as abdominal pain and spasm occur in particular in patients with irritable colon (IBS). This indicates that particular care is important when the medicine is used in this population.


Q: What are the signs that I should stop taking Pursennide?

A: Regulatory guidance notes that consultation with a healthcare provider is advised if the medicine is needed every day, if symptoms like abdominal pain persist or worsen, or if severe fluid loss or excessive diarrhea occurs.


Q: How long does it take for tolerance to Pursennide to develop?

A: The product label does not specify a timeline for the development of tolerance or habituation. However, official warnings strongly advise against long-term use due to the associated risk of developing laxative dependence and impaired intestinal function.


Q: Are there different brands of the same active ingredient as Pursennide?

A: Yes, the active ingredient in Pursennide, sennosides, is an internationally recognized compound. It is sold under many different brands and product names in various markets, often as an over-the-counter (OTC) laxative.


Q: Does the efficacy of Pursennide change over time with prolonged use?

A: The regulatory profile strictly limits use to a brief period of treatment because long-term administration may lead to impaired function of the intestine (dependence). This functional deterioration inherently results in a reduction of the medicine's effectiveness.


Q: Is Pursennide suitable for someone recovering from surgery?

A: The medicine is strictly contraindicated in conditions such as gastrointestinal obstruction and an acute surgical abdomen. For this reason, official guidance recommends a cautious approach and medical consultation following any surgery involving the abdomen or gut.


Q: Can Pursennide affect the results of any common medical tests?

A: Yes, an expected side effect is the yellow-brownish or reddish discoloration of urine by the medicine's metabolites. While this change is generally not clinically significant, it is reported in official documents and could potentially be mistaken for a finding in a medical test.


Q: Is Pursennide the same as other products containing senna?

A: Pursennide contains the active ingredient sennosides (senna glycosides). Other products containing senna use the same active compounds derived from the Senna plant, and therefore they fall under the same regulatory classification as a stimulant laxative.

How should Pursennide be stored and disposed of?

Pursennide storage and disposal requirements are strictly governed by regulatory labeling to maintain product stability and ensure public safety.

Storage Requirements

Scope Item Official Regulatory Statement
Temperature requirements Store at room temperature, typically 15 C-30 C (59 F-86 F) for similar products; some labels state no special storage precautions.
Handling/Protection Must be protected from moisture and stored in the original container.
Child-protection The product must be stored out of the sight and reach of children.

Disposal Instructions

Scope Item Official Regulatory Statement
General Disposal Rule Unused or expired medication must be disposed of according to local requirements.
Environmental Rule The product must not be disposed of via wastewater or household waste (general regulatory mandate).

The official profile specifies that disposal must comply with local and environmental regulations, and the drug should be stored to protect it from moisture and be kept away from children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pursennide found in:

A-Z Index: